

E Uyama, Department of Neurology, Kumamoto University School of Medicine, 1-1-1-Honjo, Kumamoto, 860-0811, Japan

This work was funded by the Muscular Dystrophy Campaign (UK), the MRC (Programme grant to DCR and Professor Steve Brown) and Grants-in-Aid for Scientific Research (EU) for funding. We are grateful for a Wellcome Trust Senior Fellowship in Clinical Science (DCR) and a Gates Cambridge Scholarship (SS).

Correspondence to: D C Rubinsztein; dcr1000@cus.cam.ac.uk

Received 16 September 2003

In revised form 13 October 2003

Accepted 14 October 2003

REFERENCES

- Rubinsztein DC. Lessons from animal models of Huntington's disease. *Trends Genet* 2002;**18**:202–9.
- Lunkes A, Lindenberg KS, Ben-Haiem L, Weber C, Devys D, Landwehrmeyer GB, Mandel JL, Trotter Y. Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. *Mol Cell* 2002;**10**:259–69.
- Wellington CL, Ellerby LM, Gutekunst CA, Rogers D, Warby S, Graham RK, Loubser O, van Raamsdonk J, Singaraja R, Yang YZ, Gafni J, Bredesen D, Hersch SM, Leavitt BR, Roy S, Nicholson DW, Hayden MR. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. *J Neurosci* 2002;**22**:7862–72.
- Brais B, Bouchard JP, Xie YG, Rochefort DL, Chretien N, Tome FM, Lafreniere RG, Rommens JM, Uyama E, Nohira O, Blumen S, Korczyn AD, Heutink P, Mathieu J, Duranceau A, Codere F, Fardeau M, Rouleau GA, Korczyn AD. Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy. *Nat Genet* 1998;**18**:164–7.
- Scacheri PC, Garcia C, Hebert R, Hoffman EP. Unique PABP2 mutations in "Cajuns" suggest multiple founders of oculopharyngeal muscular dystrophy in populations with French ancestry. *Am J Med Genet* 1999;**86**:477–81.
- Nakamoto M, Nakano S, Kawashima S, Ihara M, Nishimura Y, Shinde A, Kakizuka A. Unequal crossing-over in unique PABP2 mutations in Japanese patients: a possible cause of oculopharyngeal muscular dystrophy. *Arch Neurol* 2002;**59**:474–7.
- Tome FM, Chateau D, Helbling-Leclerc A, Fardeau M. Morphological changes in muscle fibers in oculopharyngeal muscular dystrophy. *Neuromuscul Disord* 1997;**7**(Suppl 1):S63–9.
- Uyama E, Tsukahara T, Goto K, Kurano Y, Ogawa M, Kim YJ, Uchino M, Arahata K. Nuclear accumulation of expanded PABP2 gene product in oculopharyngeal muscular dystrophy. *Muscle Nerve* 2000;**23**:1549–54.
- Calado A, Tome FM, Brais B, Rouleau GA, Kuhn U, Wahle E, Carmo-Fonseca M. Nuclear inclusions in oculopharyngeal muscular dystrophy consist of poly(A) binding protein 2 aggregates which sequester poly(A) RNA. *Hum Mol Genet* 2000;**9**:2321–8.
- Wytenbach A, Carmichael J, Swartz J, Furlong R, Narain Y, Rankin J, Rubinsztein DC. Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease. *Proc Natl Acad Sci U S A* 2000;**97**:2898–903.
- Bao YP, Cook LJ, O'Donovan D, Uyama E, Rubinsztein DC. Mammalian, yeast, bacterial, and chemical chaperones reduce aggregate formation and death in a cell model of oculopharyngeal muscular dystrophy. *J Biol Chem* 2002;**277**:12263–9.
- Carmichael J, Chatellier J, Woolfson A, Milstein C, Fersht AR, Rubinsztein DC. Bacterial and yeast chaperones reduce both aggregate formation and cell death in mammalian cell models of Huntington's disease. *Proc Natl Acad Sci U S A* 2000;**97**:9701–5.
- Carmichael J, Vacher C, Rubinsztein DC. The bacterial chaperonin GroEL requires GroES to reduce aggregation and cell death in a COS-7 cell model of Huntington's disease. *Neurosci Lett* 2002;**330**:270–4.
- Shanmugam V, Dion P, Rochefort D, Laganier J, Brais B, Rouleau GA. PABP2 polyalanine tract expansion causes intranuclear inclusions in oculopharyngeal muscular dystrophy. *Ann Neurol* 2000;**48**:798–802.
- Wytenbach A, Sauvageot O, Carmichael J, Diaz-Latoud C, Arrigo AP, Rubinsztein DC. Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin. *Hum Mol Genet* 2002;**11**:1137–51.
- Wytenbach A, Swartz J, Kita H, Thykjaer T, Carmichael J, Bradley J, Brown R, Maxwell M, Schapira A, Orntoft TF, Kato K, Rubinsztein DC. Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease. *Hum Mol Genet* 2001;**10**:1829–45.
- Cummings CJ, Mancini MA, Antalfy B, DeFranco DB, Orr HT, Zoghbi HY. Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. *Nat Genet* 1998;**19**:148–54.
- Chai Y, Koppenhafer SL, Bonini NM, Paulson HL. Analysis of the role of heat shock protein (Hsp) molecular chaperones in polyglutamine disease. *J Neurosci* 1999;**19**:10338–47.
- Jana NR, Tanaka M, Wang GH, Nukina N. Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity. *Hum Mol Genet* 2000;**9**:2009–18.
- Kobayashi Y, Kume A, Li M, Doyu M, Hata M, Ohtsuka K, Sobue G. Chaperones Hsp70 and Hsp40 suppress aggregate formation and apoptosis in cultured neuronal cells expressing truncated androgen receptor protein with expanded polyglutamine tract. *J Biol Chem* 2000;**275**:8772–8.
- Stenoien DL, Cummings CJ, Adams HP, Mancini MG, Patel K, DeMartino GN, Marcelli M, Weigel NL, Mancini MA. Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone. *Hum Mol Genet* 1999;**8**:731–41.
- Poirier MA, Li H, Macosko J, Cai S, Amzel M, Ross CA. Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization. *J Biol Chem* 2002;**277**:41032–7.
- Sanchez I, Mahlke C, Yuan J. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. *Nature* 2003;**421**:373–9.
- Lee VM. Amyloid binding ligands as Alzheimer's disease therapies. *Neurobiol Aging* 2002;**23**:1039–42.
- Forloni G, Colombo L, Girola L, Tagliavini F, Salmona M. Anti-amyloidogenic activity of tetracyclines: studies in vitro. *FEBS Lett* 2001;**487**:404–7.
- Krause S, Fakan S, Weis K, Wahle E. Immunodetection of poly(A)-binding protein II in the cell nucleus. *Exp Cell Res* 1994;**214**:75–82.
- Abu-Baker A, Messaed C, Laganier J, Gaspar C, Brais B, Rouleau GA. Involvement of the ubiquitin-proteasome pathway and molecular chaperones in oculopharyngeal muscular dystrophy (OPMD). *Hum Mol Genet* 2003;**12**:2609–23.
- Saleh A, Srinivasula SM, Balkir L, Robbins PD, Alnemri ES. Negative regulation of the Apaf-1 apoptosome by Hsp70. *Nat Cell Biol* 2000;**2**:476–83.
- Beere HM, Wolf BB, Cain K, Mosser DD, Mahboubi A, Kuwana T, Taylor P, Morimoto RI, Cohen GM, Green DR. Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. *Nat Cell Biol* 2000;**2**:469–75.
- Smith DL, Woodman B, Mahal A, Sathasivam K, Ghazi-Noori S, Lowden PA, Bates GP, Hockly E. Minocycline and doxycycline are not beneficial in a model of Huntington's disease. *Ann Neurol* 2003;**54**:186–96.
- Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha JH, Friedlander RM. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. *Nat Med* 2000;**6**:797–801.
- Roterman I, Kral M, Nowak M, Konieczny L, Rybarska J, Stopa B, Piekarska B, Zemanek G. Why Congo red binding is specific for amyloid proteins—model studies and a computer analysis approach. *Med Sci Monit* 2001;**7**:771–84.
- Blondelle SE, Forood B, Houghten RA, Perez-Paya E. Polyalanine-based peptides as models for self-associated beta-pleated-sheet complexes. *Biochemistry* 1997;**36**:8393–400.

CORRECTION

Giusti RM, Rutter JL, Duray PH, *et al.* *J Med Genet* 2003;**40**:787–792. During the production process errors were introduced into Table 1 of this paper. The odds ratio value for the *BRCA1* 5382insC mutation in the WAS + MECC studies should read 0.95. The 95% CI for the *BRCA2* 6174delT and the total positive frequency should read 0.89–4.56 and 1.18–3.65, respectively.